{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:00:32Z","timestamp":1790028032480,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2202,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1093\/annonc\/mdt366","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T04:07:34Z","timestamp":1379045254000},"page":"2892-2897","source":"Crossref","is-referenced-by-count":97,"title":["Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study"],"prefix":"10.1016","volume":"24","author":[{"given":"P.L.","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Polikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Prandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt366_bb0010","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas2013Version 1. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"10.1093\/annonc\/mdt366_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt366_bb0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt366_bb0025","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0030","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0035","unstructured":"PI R2013REVLIMID (lenalidomide) prescribing information. June"},{"key":"10.1093\/annonc\/mdt366_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdt366_bb0045","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt366_bb0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdt366_bb0055","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0060","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt366_bb0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt366_bb0080","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt366_bb0085","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt366_bb0090","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt366_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt366_bb0100","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2010.08376.x","article-title":"Lenalidomide-induced tumour flare reaction in mantle cell lymphoma","volume":"151","author":"Eve","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt366_bb0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdf042","article-title":"Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?","volume":"13","author":"Barista","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt366_bb0110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/11\/2892\/16701688\/mdt366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:07:43Z","timestamp":1624698463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0923753419373673"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt366","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}